日本語 
Protagenic Therapeutics, Inc. announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se, formulations containing a number of drug candidates, and their medical use, which is to treat epilepsy and seizures.
Colin Stott, Chief Operating Officer of Protagenic Therapeutics, Inc. said: “We are delighted to announce the grant of this important patent for the Company in Japan. Such a grant builds on the previous grant of the same patent in the UK (Patent GB2609814), and demonstrates the ability of the Company to continue its innovative approach and to add value and important protection to its development pipeline for shareholders. We anticipate being able to expand the grant of this patent in other territories in the future.”
The Japanese pharmaceutical market is the world’s third largest pharmaceutical market. In 2025, the Japanese pharmaceutical market is worth more than $85 billion US dollars, and the market size is anticipated to reach $93 billion US dollars by 2030.
Also Read: Infocom Launches DigiPro AI Compliance Tool for Pharma
The global epilepsy drug market size was expected to be valued at USD $11.29 billion in 2024 and is anticipated to reach around USD $18.74 billion by 2034, expanding at a CAGR of 5.20% over the forecast period from 2025 to 2034.
SOURCE: GlobeNewsWire
English